Literature DB >> 6489327

Diffusion of ciprofloxacin into prostatic fluid.

A Dalhoff, W Weidner.   

Abstract

To determine whether ciprofloxacin might be efficacious in therapy for chronic bacterial prostatitis, its diffusion into prostatic fluid was studied in ten healthy volunteers. One hour after administering 500 mg ciprofloxacin, the concentration of ciprofloxacin was measured by the agar diffusion method and bioassay. Serum levels were twice as high as in seminal fluid; however, 12 and 24 hours later concentration in seminal fluid was tenfold higher than in serum. Split ejaculates were examined to determine the secretory pattern of ciprofloxacin into seminal fluid. The two fractions also showed tenfold concentration. Ciprofloxacin concentration in expressed prostatic secretion ranged from 15 to 0.9 mg/l, thus indicating pronounced diffusion of ciprofloxacin into the prostatic fluid.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6489327     DOI: 10.1007/bf01977495

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  4 in total

1.  Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid.

Authors:  T A Stamey; E M Meares; D G Winningham
Journal:  J Urol       Date:  1970-02       Impact factor: 7.450

2.  The in vitro and in vivo activity of ciprofloxacin.

Authors:  H J Zeiler; K Grohe
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

3.  In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.

Authors:  F W Heessen; H L Muytjens
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

4.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

  4 in total
  25 in total

Review 1.  The role of quinolones in the treatment of chronic bacterial prostatitis.

Authors:  K G Naber
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Chronic bacterial prostatitis: therapeutic experience with ciprofloxacin.

Authors:  W Weidner; H G Schiefer
Journal:  Infection       Date:  1991       Impact factor: 3.553

3.  A new method for assaying antimicrobials in the prostate.

Authors:  A C Philpott; E D Crawford; G J Miller
Journal:  Infection       Date:  1991       Impact factor: 3.553

4.  The treatment of chronic bacterial prostatitis.

Authors:  A Pfau
Journal:  Infection       Date:  1991       Impact factor: 3.553

5.  Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration.

Authors:  K Borner; G Höffken; H Lode; P Koeppe; C Prinzing; P Glatzel; R Wiley; P Olschewski; B Sievers; D Reinitz
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

6.  Penetration of ciprofloxacin into female pelvic tissues.

Authors:  S Segev; E Rubinstein; J Shick; O Rabinovitch; M Dolitsky
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

7.  Diffusion of ciprofloxacin into prostatic fluid.

Authors:  A Dalhoff; W Weidner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

8.  Fleroxacin (Ro 23-6240) distribution in canine prostatic tissue and fluids.

Authors:  T C Gasser; P H Graversen; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

9.  Ciprofloxacin concentrations in tonsils following single or multiple administrations.

Authors:  N Falser; A Dalhoff; H Weuta
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.